

GLAXOSMITHKLINE PLC  
Form 6-K  
April 01, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc ('Company').

On 31 March 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.66 per Ordinary Share, and notional ADSs at a price of \$46.80 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2015 to 31 March 2015:

Non Executive Director	Ordinary Shares	No. of ADSs
Sir Christopher Gent	3,991.060	
Professor Sir Roy Anderson	458.972	
Dr Stephanie Burns		486.201
Stacey Cartwright	339.240	
Lynn Elsenhans		1,103.464
Sir Philip Hampton	339.240	
Judy Lewent		539.049
Sir Deryck Maughan		1,479.741
Dr Daniel Podolsky		1,109.806
Urs Rohner	339.240	
Tom de Swaan	419.061	
Jing Ulrich		306.518
Hans Wijers	339.240	

The Company and the Non-Executive Directors were informed of these allocations on 1 April 2015.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Company Secretary

1 April 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 01, 2015

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc